Drug intelligence / Profile preview

JT-1801

Development stage: Phase 4
Lead developer: North China Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

JT-1801 is an erythropoietin receptor (EPO receptor) agonist biosimilar drug. It appears to be a biosimilar to darbepoetin alfa (NESP®). The drug is being developed for the treatment of anemia, particularly anemia associated with chronic kidney disease. It is administered intravenously.

Other names: darbepoetin alfa biosimilar

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on JT-1801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JT-1801.

Explore the full profile